Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

CRISP-HR Therapeutics

Main focus: Next-generation gene editing

Company stage: Pre-clinical

Diseases (gene editing): Rare diseases and metabolic indications, specifically liver and pancreatic disorders

Genome editing tool: CRISPR-Cas9-HR

Funding stage: Private

Location: San Carlos, CA, USA


CRISP-HR Therapeutics has developed a novel CRISPR-Cas9 system that favours the cellular repair mechanism called homologous recombination (HR) over another mechanism called non-homologous end joining (NHEJ), enabling higher rates of transgene insertions. While the company yet has to disclose its lead programmes, it has revealed that it will initially focus on rare disease and metabolic conditions.


HashtagCRISP-HR Therapeutics

Company: CRISP-HR Therapeutics
Search CRISPR Medicine